e-learning
resources
Virtual 2020
Pre-Congress Content
Pharmacological management of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Withdrawal of ICS in patients with COPD
A. Nielsen (Roskilde, Denmark), O. Hilberg (Vejle, Denmark), J. Jensen (Copenhagen, Denmark), A. Løkke (VejleVejle, Denmark)
Source:
Virtual Congress 2020 – Pharmacological management of COPD
Session:
Pharmacological management of COPD
Session type:
E-poster session
Number:
2420
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Nielsen (Roskilde, Denmark), O. Hilberg (Vejle, Denmark), J. Jensen (Copenhagen, Denmark), A. Løkke (VejleVejle, Denmark). Withdrawal of ICS in patients with COPD. 2420
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline
Source: International Congress 2018 – COPD management
Year: 2018
ICS discontinuation guidelines in COPD
Source: Virtual Congress 2020 – German programme 2020
Year: 2020
Adherence of stable COPD patients to inhaled pharmacotherapy
Source: Annual Congress 2011 - COPD management
Year: 2011
The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
ERS guideline on withdrawal of inhaled corticosteroids in COPD
Source: ERS webinar 2021: ERS guideline on withdrawal of inhaled corticosteroids in COPD
Year: 2021
Variability in asthma severity among steroid-naive patients previously receiving short-acting beta
2
-agonists
Source: Eur Respir J 2003; 22: Suppl. 45, 410s
Year: 2003
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004
Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
Inhaled medication use in asthma and COPD Roma/Gypsies patients
Source: Eur Respir J 2005; 26: Suppl. 49, 610s
Year: 2005
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Association of COPD inhaled medication adherence with hospitalization for acute exacerbation of COPD (AECOPD)
Source: International Congress 2017 – COPD management
Year: 2017
Compliance of COPD patients to their treatment
Source: Eur Respir J 2003; 22: Suppl. 45, 244s
Year: 2003
Adhesion to inhaled treatment in patients with asthma and COPD
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020
Inhaled corticosteroid therapy on admission of hospitalized patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 243s
Year: 2002
Withdrawal of inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: who is suitable for a trial of withdrawal?
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019
How the bronchodilatator in COPD patients works
Source: Eur Respir J 2004; 24: Suppl. 48, 288s
Year: 2004
Discontinuation of inhaled corticosteroid treatment in patients with COPD diagnosed in general practice
Source: Eur Respir J 2002; 20: Suppl. 38, 212s
Year: 2002
Withdrawal of inhaled corticosteroids in people with chronic obstructive pulmonary disease (COPD) in primary care – a randomised controlled trial
Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD
Year: 2005
Nonadherence with inhaled preventer therapy in severe asthmatic patients on long-term omalizumab
Source: Eur Respir J, 52 (2) 1801025; 10.1183/13993003.01025-2018
Year: 2018
Bronchodilator efficacy of tiotropium in patients with mild COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 616s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept